Opioid use disorder (OUD) is best treated with medications for opioid use disorder (MOUD)—methadone, buprenorphine (including long‑acting injectables), and naltrexone—combined with behavioral and social support. Recent systematic reviews and policy analyses reaffirm that MOUD dramatically reduces overdose, illicit use, and mortality compared with abstinence‑only or psychosocial‑only approaches, and that certain formulations (e.g., extended‑release buprenorphine) may offer advantages in abstinence and retention for many patients [1][2][3][4].

Most effective therapy classes

1. MOUD as the gold standard

Evidence consistently shows:

• MOUD vs behavioral therapy alone

• Behavioral‑only treatment yields much shorter retention:

  • Median retention time was 1.8× shorter than with buprenorphine, 2.2× shorter than with naltrexone, and 4.8× shorter than with methadone in one large analysis [2].

• MOUD significantly reduces:

  • Illicit opioid use.

  • Overdose and all‑cause mortality.

  • Relapse and re‑entry into treatment [1][2][3].

• MOUD plus behavioral support outperforms either medication or counseling alone in sustaining recovery and improving quality of life [2].

2. Methadone and sublingual buprenorphine

• Methadone

• Long‑acting full agonist; strong evidence for:

  • Excellent retention—often the highest among MOUD options.

  • Substantial reduction in overdose and all‑cause mortality [3].

• Constraints:

  • Delivered via licensed opioid treatment programs (OTPs); daily or frequent supervised dosing.

  • Higher risk of respiratory depression and overdose if misused.

• Sublingual buprenorphine (with or without naloxone)

• Partial agonist with ceiling effect on respiratory depression; more flexible take‑home dosing.

• Mortality up to ~6% lower vs methadone monotherapy in some cohorts; lower overdose risk [2].

• Retention generally good but often slightly lower than methadone in many real‑world settings.

3. Extended‑release buprenorphine (BUP‑XR and other LAIs)

Recent network meta‑analyses and large observational cohorts show:

• Retention

• Monthly BUP‑XR had the highest probability of retention at 3, 6, 12, and 18 months compared with:

  • Other buprenorphine LAIs.

  • Transmucosal buprenorphine.

  • Buprenorphine implants.

• Retention with BUP‑XR was comparable to methadone, including in mixed RCT/real‑world analyses [4][5].

• Abstinence / illicit opioid use

• BUP‑XR showed the highest probability of abstinence at all time points:

  • vs transmucosal buprenorphine: RR of illicit use ≈ 1.99 favoring BUP‑XR.

  • vs methadone: RR ≈ 2.66 favoring BUP‑XR (lower illicit use with BUP‑XR) [4].

• RCT‑only analyses were directionally similar, though some estimates were borderline due to smaller sample sizes [4].

• Safety and quality of life

• Safety profiles of BUP‑XR and comparators were generally similar with no consistent safety red flags [4].

• Limited evidence suggests better recovery and quality‑of‑life scores (e.g., SURE measure) with BUP‑XR versus other buprenorphine formulations, though confidence intervals were wide [4][5].

• Practical advantages

• Monthly dosing improves adherence by removing daily pill burden and opportunities to miss doses or divert medication.

• Particularly helpful for patients with unstable housing, complex psychosocial needs, or difficulty with daily adherence.

4. Naltrexone (especially extended‑release formulations)

• Mechanism: Opioid antagonist blocking effects of opioids; requires 7–10 days opioid‑free before initiation to avoid precipitated withdrawal [2].

• Effectiveness:

• Extended‑release injectable or implantable naltrexone is more effective than oral naltrexone for reducing illicit opioid use and relapse due to better adherence [2][6].

• Best suited for highly motivated patients who can complete detox and commit to blocking opioid effects.

• Risks:

• Loss of tolerance means relapse can carry high overdose risk if patients resume prior doses.

5. Non‑MOUD approaches (less effective for dependence)

• Symptomatic withdrawal management only (α2 agonists, antiemetics, etc.) provides short‑term relief but:

• Does not reduce cravings, overdose risk, or long‑term relapse in the way MOUD does [2].

• Recommended only as a bridge or adjunct, not as stand‑alone treatment.

Which therapies are “most effective” overall?

Based on current evidence:

• For population‑level impact on dependence, overdose, and mortality:

• MOUD broadly (methadone, buprenorphine, naltrexone) is decisively more effective than abstinence‑based or psychosocial‑only care [1][2][3][6].

• Within MOUD:

• Methadone: strongest long‑term retention; large mortality benefit; preferred for patients with very high opioid tolerance and long‑standing severe OUD, when OTP access is feasible.

• Buprenorphine (including BUP‑XR):

  • BUP‑XR stands out for:

  • Highest abstinence rates.

  • Retention comparable to methadone but with lower overdose risk and simpler take‑home logistics [4][5].

  • Sublingual buprenorphine remains crucial for flexible, office‑based care.

• Extended‑release naltrexone: valuable for post‑detox maintenance in motivated patients who prefer or require antagonist therapy (e.g., professionals under monitoring, justice‑involved populations).

System-level levers to reduce dependence

Evidence and modeling studies suggest:

• Scaling up MOUD access and retention—including:

• Reducing regulatory barriers (e.g., OTP restrictions, prescriber limits).

• Integrating MOUD into primary care and telehealth.

• Using digital tools to support adherence and retention [1][3][5].

• Enhancing MOUD with behavioral and social supports:

• Housing, employment, recovery coaching, and peer support improve stability and reduce relapse.

• Widespread naloxone distribution:

• Substantially reduces overdose deaths and supports survival long enough to engage in MOUD [3][6].